

The Royal Women's Hospital Melbourne Joins CLEO Ovarian Cancer Trial

Highlights

- **Leading specialist hospital for women's health, the Royal Women's Hospital (the Women's) Melbourne to participate in CLEO's ovarian cancer trial**
- **The Women's inclusion is designed to broaden patient sampling that will ultimately be used to verify and optimise CLEO's ovarian cancer blood test**
- **Focus remains on U.S. clinical trial with patient recruitment progressing and program on track to support FDA submission in CY2025**

MELBOURNE, AUSTRALIA, 27 November 2024: Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce further progress across clinical trials for its simple and accurate blood test for the early detection of ovarian cancer.

Clinical Trials Advancing

The Royal Women's Hospital Melbourne Joins CLEO Trial

CLEO has expanded its ovarian cancer Australian trial with the inclusion of the Royal Women's Hospital as a participating site, with eminent gynaecological oncology specialist, Associate Professor Orla McNally, acting as Principal Investigator. The Women's is Australia's leading specialist hospital for women's health where the partnership aims to:

- complement CLEO's broader trial strategy by increasing the cohort of patient samples;
- expand market awareness for CLEO;
- verify and optimise CLEO's ovarian cancer blood test; and
- potentially bolster the U.S. trial.

Commenting on the partnership, Associate Professor Orla McNally, Director of Oncology and Dysplasia Service at the Women's, said:

"Early and accurate detection of ovarian cancer is a critical unmet need. CLEO's ovarian cancer blood test has the potential to better inform clinical workflows for clinicians to ultimately provide better health outcomes for women.

We are pleased to be working with Cleo Diagnostics on this shared vision."

U.S. Trials

Primary focus for the Company is the U.S. clinical trial in the world's largest diagnostic market. The trial will underpin a Food and Drug Administration (FDA) 510(k) submission which remains on track for

Cleo Diagnostics Ltd ASX:COV

Level 2, 480 Collins Street, Melbourne, VIC, 3000
ACN 655 717 169 T +61 3 9614 0600 E office@cleodx.com

Directors

Chair and Non-Executive Director **Adrien Wing**
Chief Executive Officer and Executive Director **Dr Richard Allman**
Chief Scientific Officer and Executive Director **Dr Andrew Stephens**
Non-Executive Director and Lead Medical Advisor **Professor Tom Jobling**
Non-Executive Director **Lucinda Nolan**

For personal use only

CY2025. Patient recruitment continues to progress as planned across eight medical trial locations. Patient samples are being collected in line with trial objectives targeting a minimum of 500 patients with diversity representative of the U.S. population.

The Company is also progressing multiple commercial initiatives in parallel with respect to its reimbursement strategy, international collaborations, grant applications, and market engagement of early adopters to ensure the CLEO ovarian cancer blood test is available quickly in initial targeted markets.

Commenting on the trial progress, CLEO Chief Executive, Richard Allman, said:

"The addition of the Royal Women's Hospital is important to our trials strategy in the context that CLEO is focused on working with leading organisations in the treatment of ovarian cancer.

Our U.S. trials are progressing well which continues to support our plan for FDA submission in 2025. In parallel, we are working across a number of commercial initiatives that will ensure that CLEO's ovarian cancer blood test is positioned well to be available in our initial markets as soon as possible."

-ENDS-

This ASX announcement was authorised for release on behalf of the Cleo Diagnostics Ltd Board by:

Richard Allman, Chief Executive Officer.

For more information, contact:

Richard Allman
Chief Executive Officer
+613 9614 0600
office@cleodx.com

Elvis Jurcevic
Investor Relations
+614 08 268 271
ej@cleodx.com

Forward Looking Statements: This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Cleo and certain of the plans and objectives of Cleo with respect to these items. These forward-looking statements are not historical facts but rather are based on Cleo's current expectations, estimates and projections about the industry in which Cleo operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Cleo, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Cleo cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Cleo only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Cleo will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.



About Cleo Diagnostics Ltd ASX:COV

CLEO aims to bring to market a simple blood test for the accurate and early diagnosis of ovarian cancer based on the novel patented CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is largely absent in non-malignant disease. The test aims to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by diagnostic laboratories worldwide.

The platform is backed by over 10 years of scientific Research & Development at the Hudson Institute of Medical Research, with two clinical studies conducted with over 500 patients. Pursuant to a licence agreement with the Hudson Institute of Medical Research, CLEO has a worldwide exclusive licence to commercialise the intellectual property which underpins its operations and the ovarian cancer tests.

The clinical unmet worldwide need is urgent. An accurate and early detection blood test could shift survivability for ovarian cancer significantly as seen with other cancers. CLEO is advancing the availability of its simple blood test, under a modular execution strategy which is designed to eventually address all ovarian cancer detection markets with specific tests including surgical triage, recurrence, high risk, and early-stage screening.

For personal use only

